Image 1 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 01)
Divalproex Sodium Tablet, Extended Release
Product Images NDC 68180-261
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Divalproex Sodium (NDC 68180-261). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Lupin Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
Image 2 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 02)
This text appears to be a graph or chart showing the reduction in CPS (presumably referring to some sort of medical measurement) rate when patients are treated with Divalproex Sodium Delayed-Release compared to a placebo. The graph shows that there is a 50% improvement in patients. However, without more information and context, it is difficult to provide a more detailed description.*
Image 3 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 03)
Image 4 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 04)
Image 5 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 05)
Each extended-release tablet of Divalproex Sodium contains valproic acid and is used to treat seizures and bipolar disorder. The usual dosage information is available in the accompanying prescribing information. The tablets must be stored in a tightly closed container at a controlled room temperature. Dispensing must be done with a medication guide provided separately to each patient. This drug is manufactured by Lupin in India and the code number is MH/DRUGS/25-ND/59.*
Image 6 (D95f9b1b F1e4 4ae4 A215 7317fb1ca565 06)
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
